journal
MENU ▼
Read by QxMD icon Read
search

Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research

journal
https://www.readbyqxmd.com/read/30224119/correction
#1
(no author information available yet)
No abstract text is available yet for this article.
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224118/quality-adjusted-life-years-without-constant-proportionality
#2
Benjamin M Craig, Kim Rand, Henry Bailey, Peep F M Stalmeier
BACKGROUND: A quality-adjusted life-year is a common unit of measurement in health valuation. Under its constant proportionality assumption, the value of a quality-adjusted life span is defined as the product of preference weight and life span. OBJECTIVES: To empirically identify an alternative functional relationship between life span and value by relaxing the constant proportionality assumption. METHODS: Using an online survey, 5367 respondents completed 30 to 40 paired comparisons where each involved a choice between two health outcomes: one with a longer life span and health problems (five-level EuroQol five-dimensional questionnaire) and the other with a shorter life span and no problems (time trade-off pair)...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224117/evaluating-the-content-validity-of-four-performance-outcome-measures-in-patients-with-elective-hip-replacements-and-hip-fractures
#3
Rachel Ballinger, Cicely Kerr, Fiona Mowbray, Elizabeth Nicole Bush
OBJECTIVES: To assess the content validity of performance outcome (PerfO) measures for use with patients undergoing hip fracture (HF) surgery and elective total hip replacement (eTHR). METHODS: This study was a substudy of a broader evaluation of measurement properties of PerfO measures. The PerfO measures assessed were timed up and go (TUG), four-step stair climb (4SC), long stair climb (LSC), and repeated chair stand (RCS). For this substudy, HF and eTHR participants were interviewed to evaluate the relevance and difficulty of each PerfO measure...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224116/evaluation-of-the-measurement-properties-of-four-performance-outcome-measures-in-patients-with-elective-hip-replacements-elective-knee-replacements-or-hip-fractures
#4
Helen Doll, Brittany Gentile, Elizabeth Nicole Bush, Rachel Ballinger
OBJECTIVES: To evaluate the measurement properties of four performance outcome (PerfO) measures (timed up and go, four-step stair climb, long stair climb, and repeated chair stand) in three patient populations(elective total hip replacement [eTHR], elective total knee replacement [eTKR], and hip fracture [HF]). METHODS: A cross-sectional and longitudinal design was used to assess the PerfO measurement properties using the US Food and Drug Administration guidance for industry around patient-reported outcome measures to support labeling claims...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224115/development-and-validation-of-an-algorithm-for-identifying-patients-with-hemophilia-a-in-an-administrative-claims-database
#5
Jennifer Lyons, Vibha Desai, Yaping Xu, Greg Ridgeway, William Finkle, Paul Solari, Sean Sullivan, Stephan Lanes
BACKGROUND: The accuracy with which hemophilia A can be identified in claims databases is unknown. OBJECTIVE: Develop and validate an algorithm using predictive modeling supported by machine learning to identify patients with hemophilia A in an administrative claims database. METHODS: We first created a screening algorithm using medical and pharmacy claims to identify potential hemophilia A patients in the US HealthCore Integrated Research Database between January 1, 2006 and April 30, 2015...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224114/minimally-important-difference-of-the-eq-5d-5l-index-score-in-adults-with-type-2-diabetes
#6
Nathan S McClure, Fatima Al Sayah, Arto Ohinmaa, Jeffrey A Johnson
BACKGROUND: The EuroQol five-dimensional questionnaire (EQ-5D) is a generic preference-based measure of health-related quality of life, and several studies have made attempts to estimate the minimally important difference (MID) for the EQ-5D index score. OBJECTIVES: To estimate the MID of the five-level EQ-5D (EQ-5D-5L) index score in a population-based sample of adults with type 2 diabetes and to explore whether the MID estimate varies by baseline index score and the direction of change in health status...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224113/cost-sharing-of-disease-modifying-treatments-dmts-as-policy-lever-to-improve-dmts-access-in-multiple-sclerosis
#7
Hui Shao, Charles Stoecker, Alisha M Monnette, Lizheng Shi
OBJECTIVES: To understand the nonlinear relationship between out-of-pocket (OOP) payments and disease-modifying treatment (DMT) use and adherence, primarily to pinpoint the threshold at which the use of DMTs becomes price sensitive. METHODS: Individuals with more than two multiple sclerosis (MS) diagnoses (International Classification of Diseases, Ninth Revision code 340) were identified from the MarketScan database (2006-2009). Heterogeneity in treatment was normalized by calculating an annual OOP payment as the average OOP payment for purchasing a fixed basket of DMTs at the insurance plan level...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224112/on-the-value-of-the-umbilical-cord-blood-supply
#8
Aaron Strong, Tadeja Gračner, Peggy Chen, Kandice Kapinos
BACKGROUND: Several public cord blood banks are struggling financially, and the question remains as to whether additional allocations of funds to them are justified. OBJECTIVES: To estimate the social benefits of public cord blood bank inventory net of cord blood banks' operational costs. METHODS: We used publicly available data from the Health Resources and Service Administration on the number of annual cord blood transplants as well as the patient age distribution in 2010, and the survival estimates between 2008 and 2012 for the several diseases treated by cord blood transplantation...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224111/physicians-decision-making-on-adoption-of-new-technologies-and-role-of-coverage-with-evidence-development-a-qualitative-study
#9
Susanne Felgner, Patricia Ex, Cornelia Henschke
OBJECTIVES: To foster value-based pricing and coverage with evidence development in Germany, certain new diagnostic and treatment methods have been subject to a benefit assessment since 2016 to determine their reimbursement. Although this is a paradigm shift, the German approach is limited to some few specific technologies for which reimbursement is requested. As physicians encounter this regulatory instrument, the aim of the study was to understand physicians' decision making regarding the adoption of new medical technologies and to identify their perspectives on the evidence base and financing with additional reimbursement systems...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224110/from-the-past-to-the-present-insurer-coverage-frameworks-for-next-generation-tumor-sequencing
#10
Julia R Trosman, Christine B Weldon, William J Gradishar, Al B Benson, Massimo Cristofanilli, Allison W Kurian, James M Ford, Alan Balch, John Watkins, Kathryn A Phillips
Next-generation sequencing promises major advancements in precision medicine but faces considerable challenges with insurance coverage. These challenges are especially important to address in oncology in which next-generation tumor sequencing (NGTS) holds a particular promise, guiding the use of life-saving or life-prolonging therapies. Payers' coverage decision making on NGTS is challenging because this revolutionary technology pushes the very boundaries of the underlying framework used in coverage decisions...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224109/cost-analyses-of-genomic-sequencing-lessons-learned-from-the-medseq-project
#11
Kurt D Christensen, Kathryn A Phillips, Robert C Green, Dmitry Dukhovny
OBJECTIVE: To summarize lessons learned while analyzing the costs of integrating whole genome sequencing into the care of cardiology and primary care patients in the MedSeq Project by conducting the first randomized controlled trial of whole genome sequencing in general and specialty medicine. METHODS: Case study that describes key methodological and data challenges that were encountered or are likely to emerge in future work, describes the pros and cons of approaches considered by the study team, and summarizes the solutions that were implemented...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224108/using-big-data-in-the-cost-effectiveness-analysis-of-next-generation-sequencing-technologies-challenges-and-potential-solutions
#12
Sarah Wordsworth, Brett Doble, Katherine Payne, James Buchanan, Deborah A Marshall, Christopher McCabe, Dean A Regier
Next-generation sequencing (NGS) is considered to be a prominent example of "big data" because of the quantity and complexity of data it produces and because it presents an opportunity to use powerful information sources that could reduce clinical and health economic uncertainty at a patient level. One obstacle to translating NGS into routine health care has been a lack of clinical trials evaluating NGS technologies, which could be used to populate cost-effectiveness analyses (CEAs). A key question is whether big data can be used to partially support CEAs of NGS...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224107/valuation-of-health-and-nonhealth-outcomes-from-next-generation-sequencing-approaches-challenges-and-solutions
#13
Dean A Regier, Deirdre Weymann, James Buchanan, Deborah A Marshall, Sarah Wordsworth
BACKGROUND: Next-generation sequencing (NGS) technologies have seen variable adoption in the clinic. This is partly due to a lack of clinical and economic studies, with the latter increasingly challenged to examine patient preferences for health and nonhealth outcomes (e.g., false-positive rate). OBJECTIVES: To conduct a structured review of studies valuing patients' preference-based utility for NGS outcomes, to highlight identified methodological challenges, and to consider how studies addressed identified challenges...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224106/methodological-issues-in-assessing-the-economic-value-of-next-generation-sequencing-tests-many-challenges-and-not-enough-solutions
#14
Kathryn A Phillips, Patricia A Deverka, Deborah A Marshall, Sarah Wordsworth, Dean A Regier, Kurt D Christensen, James Buchanan
BACKGROUND: Clinical use of next-generation sequencing (NGS) tests has been increasing, but few studies have examined their economic value. Several studies have noted that there are methodological challenges to conducting economic evaluations of NGS tests. OBJECTIVE: Our objective was to examine key methodological challenges for conducting economic evaluations of NGS tests, prioritize these challenges for future research, and identify how studies have attempted solutions to address these challenges...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224105/assessing-the-value-of-next-generation-sequencing-technologies-an-introduction
#15
EDITORIAL
Kathryn A Phillips
No abstract text is available yet for this article.
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224104/are-we-ready-to-use-constrained-optimization-in-health-outcomes-research
#16
EDITORIAL
Stephanie R Earnshaw
No abstract text is available yet for this article.
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30224103/application-of-constrained-optimization-methods-in-health-services-research-report-2-of-the-ispor-optimization-methods-emerging-good-practices-task-force
#17
William Crown, Nasuh Buyukkaramikli, Mustafa Y Sir, Praveen Thokala, Alec Morton, Deborah A Marshall, Jonathan C Tosh, Maarten J Ijzerman, William V Padula, Kalyan S Pasupathy
BACKGROUND: Constrained optimization methods are already widely used in health care to solve problems that represent traditional applications of operations research methods, such as choosing the optimal location for new facilities or making the most efficient use of operating room capacity. OBJECTIVES: In this paper we illustrate the potential utility of these methods for finding optimal solutions to problems in health care delivery and policy. To do so, we selected three award-winning papers in health care delivery or policy development, reflecting a range of optimization algorithms...
September 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30098678/advocating-a-paradigm-shift-in-health-state-valuations-the-estimation-of-time-preference-corrected-qaly-tariffs
#18
Marcel F Jonker, Bas Donkers, Esther W de Bekker-Grob, Elly A Stolk
BACKGROUND: Despite evidence of nonproportional trade-offs in time trade-off exercises and the explicit incorporation of exponential discounting in health technology assessment calculations, quality-adjusted life-year (QALY) tariffs are currently still established under the assumption of linear time preferences. OBJECTIVES: The aim of this study was to introduce a general method of accommodating for nonlinear time preferences in discrete choice experiment (DCE) duration studies and to evaluate its impact on estimated QALY tariffs...
August 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30098677/initial-development-and-content-validation-of-a-health-related-symptom-index-for-persons-either-treated-or-monitored-for-anal-high-grade-squamous-intraepithelial-lesions
#19
Jack E Burkhalter, Thomas M Atkinson, J Berry-Lawhorn, Stephen Goldstone, Mark H Einstein, Timothy J Wilkin, Jeannette Lee, David Cella, Joel M Palefsky
BACKGROUND: Anal cancer, caused by oncogenic types of human papillomavirus, is a growing problem in the United States. A key focus of anal cancer prevention has been screening for and treating precancerous high-grade squamous intraepithelial anal lesions (HSILs). OBJECTIVES: To develop a health-related symptom index for HSIL using qualitative techniques because anal HSIL and its treatment may have a negative impact on health-related quality of life (HRQOL), and no HRQOL measure specific to this condition and treatment currently exists...
August 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30098676/qualitative-research-to-explore-the-patient-experience-of-x-linked-hypophosphatemia-and-evaluate-the-suitability-of-the-bpi-sf-and-womac%C3%A2-as-clinical-trial-end-points
#20
Christina Theodore-Oklota, Nicola Bonner, Holly Spencer, Rob Arbuckle, Chao-Yin Chen, Alison Skrinar
BACKGROUND: X-linked hypophosphatemia (XLH) is a rare genetic disorder characterized by renal phosphate wasting and defective bone mineralization. Symptoms include bone pain, joint pain, stiffness, and fatigue. Published evidence regarding the patient experience of XLH is sparse and no XLH-specific outcome measures have been validated. OBJECTIVES: To understand the symptoms, impacts, and patient experience of XLH and to evaluate the face and content validity of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC®) and the Brief Pain Inventory Short Form (BPI-SF) for use as end points in XLH clinical trials...
August 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
journal
journal
34615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"